{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cannabidiol", "cannabinoid receptors", "cannabinoids", "gastrointestinal barrier permeability", "gastrointestinal motility", "gut diseases"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38928387", "DateCompleted": {"Year": "2024", "Month": "06", "Day": "27"}, "DateRevised": {"Year": "2024", "Month": "06", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["6682", "10.3390/ijms25126682"], "ArticleDate": [{"Year": "2024", "Month": "06", "Day": "18"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "12", "PubDate": {"Year": "2024", "Month": "Jun", "Day": "18"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases.", "Abstract": {"AbstractText": ["Cannabinoids and their receptors play a significant role in the regulation of gastrointestinal (GIT) peristalsis and intestinal barrier permeability. This review critically evaluates current knowledge about the mechanisms of action and biological effects of endocannabinoids and phytocannabinoids on GIT functions and the potential therapeutic applications of these compounds. The results of ex vivo and in vivo preclinical data indicate that cannabinoids can both inhibit and stimulate gut peristalsis, depending on various factors. Endocannabinoids affect peristalsis in a cannabinoid (CB) receptor-specific manner; however, there is also an important interaction between them and the transient receptor potential cation channel subfamily V member 1 (TRPV1) system. Phytocannabinoids such as \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD) impact gut motility mainly through the CB1 receptor. They were also found to improve intestinal barrier integrity, mainly through CB1 receptor stimulation but also via protein kinase A (PKA), mitogen-associated protein kinase (MAPK), and adenylyl cyclase signaling pathways, as well as by influencing the expression of tight junction (TJ) proteins. The anti-inflammatory effects of cannabinoids in GIT disorders are postulated to occur by the lowering of inflammatory factors such as myeloperoxidase (MPO) activity and regulation of cytokine levels. In conclusion, there is a prospect of utilizing cannabinoids as components of therapy for GIT disorders."]}, "AuthorList": [{"Identifier": ["0000-0001-8480-0627"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Crowley", "ForeName": "Kijan", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Kiraga", "ForeName": "\u0141ukasz", "Initials": "\u0141"}, {"Identifier": ["0000-0001-6046-8703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Miszczuk", "ForeName": "Edyta", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Skiba", "ForeName": "Sergiusz", "Initials": "S"}, {"Identifier": ["0000-0003-1094-8930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Research and Processing Seed, Institute of Natural Fibers and Medicinal Plants-National Research Institute, Wojska Polskiego 71b, 60-630 Poznan, Poland."}], "LastName": "Banach", "ForeName": "Joanna", "Initials": "J"}, {"Identifier": ["0000-0002-3203-7209"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Latek", "ForeName": "Urszula", "Initials": "U"}, {"Identifier": ["0000-0003-0202-2169"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Mendel", "ForeName": "Marta", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Pharmacology and Toxicology, Department of Preclinical Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, Ciszewskiego 8, 02-786 Warsaw, Poland."}], "LastName": "Ch\u0142opecka", "ForeName": "Magdalena", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cannabinoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Endocannabinoids"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Cannabinoids"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gastrointestinal Motility"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Gastrointestinal Diseases"}, {"QualifierName": ["drug effects"], "DescriptorName": "Permeability"}, {"QualifierName": ["metabolism", "drug effects"], "DescriptorName": "Intestinal Mucosa"}, {"QualifierName": ["metabolism"], "DescriptorName": "Endocannabinoids"}], "CoiStatement": "The authors declare no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Di Marzo V., Izzo A.A. Endocannabinoid overactivity and intestinal inflammation. Gut. 2006;55:1373\u20131376. doi: 10.1136/gut.2005.090472.", "ArticleIdList": ["10.1136/gut.2005.090472", "PMC1856409", "16966693"]}, {"Citation": "Mechoulam R., Hanu\u0161 L.O., Pertwee R., Howlett A.C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 2014;15:757\u2013764. doi: 10.1038/nrn3811.", "ArticleIdList": ["10.1038/nrn3811", "25315390"]}, {"Citation": "Corcoran L., Roche M., Finn D.P. International Review of Neurobiology. Volume 125. Elsevier; Amsterdam, The Netherlands: 2015. The Role of the Brain\u2019s Endocannabinoid System in Pain and Its Modulation by Stress; pp. 203\u2013255.", "ArticleIdList": ["26638768"]}, {"Citation": "Zielonka D.M., Kiraga \u0141., Koz\u0142owski R.M. Medical potential of Cannabis: An overview. Handb. Nat. Fibres. 2020;2:419\u2013448."}, {"Citation": "Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002;68\u201369:619\u2013631. doi: 10.1016/S0090-6980(02)00060-6.", "ArticleIdList": ["10.1016/S0090-6980(02)00060-6", "12432948"]}, {"Citation": "Turcotte C., Blanchet M.-R., Laviolette M., Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell. Mol. Life Sci. 2016;73:4449\u20134470. doi: 10.1007/s00018-016-2300-4.", "ArticleIdList": ["10.1007/s00018-016-2300-4", "PMC5075023", "27402121"]}, {"Citation": "Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61\u201365. doi: 10.1038/365061a0.", "ArticleIdList": ["10.1038/365061a0", "7689702"]}, {"Citation": "Howlett A.C., Abood M.E. CB1 & CB2 Receptor Pharmacology. Adv. Pharmacol. 2017;80:169\u2013206. doi: 10.1016/bs.apha.2017.03.007.", "ArticleIdList": ["10.1016/bs.apha.2017.03.007", "PMC5812699", "28826534"]}, {"Citation": "Chiarlone A., Bellocchio L., Bl\u00e1zquez C., Resel E., Soria-G\u00f3mez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., et al. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. USA. 2014;111:8257\u20138262. doi: 10.1073/pnas.1400988111.", "ArticleIdList": ["10.1073/pnas.1400988111", "PMC4050577", "24843137"]}, {"Citation": "Starowicz K., Finn D.P. Chapter Thirteen\u2014Cannabinoids and Pain: Sites and Mechanisms of Action. In: Kendall D., Alexander S.P.H., editors. Advances in Pharmacology. Volume 80. Cannabinoid Pharmacology; Academic Press; Cambridge, MA, USA: 2017. pp. 437\u2013475.", "ArticleIdList": ["28826543"]}, {"Citation": "Pacher P., B\u00e1tkai S., Kunos G. Cardiovascular Pharmacology of Cannabinoids. In: Pertwee R.G., editor. Cannabinoids. Springer; Berlin/Heidelberg, Germany: 2005. pp. 599\u2013625. Handbook of Experimental Pharmacology.", "ArticleIdList": ["PMC2228270", "16596789"]}, {"Citation": "Massa F., Storr M., Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J. Mol. Med. 2005;83:944\u2013954. doi: 10.1007/s00109-005-0698-5.", "ArticleIdList": ["10.1007/s00109-005-0698-5", "16133420"]}, {"Citation": "McCallum R.W., Bashashati M. Cannabis for Gastroparesis: Hype or Hope? Am. J. Gastroenterol. 2019;114:865\u2013866. doi: 10.14309/ajg.0000000000000277.", "ArticleIdList": ["10.14309/ajg.0000000000000277", "31135448"]}, {"Citation": "Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.-U., Zieglg\u00e4nsberger W., Lutz B., Rammes G. Cannabinoid Receptor Type 1 Located on Presynaptic Terminals of Principal Neurons in the Forebrain Controls Glutamatergic Synaptic Transmission. J. Neurosci. 2006;26:5794\u20135799. doi: 10.1523/jneurosci.0372-06.2006.", "ArticleIdList": ["10.1523/jneurosci.0372-06.2006", "PMC6675276", "16723537"]}, {"Citation": "Pagotto U., Marsicano G., Cota D., Lutz B., Pasquali R. The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance. Endocr. Rev. 2006;27:73\u2013100. doi: 10.1210/er.2005-0009.", "ArticleIdList": ["10.1210/er.2005-0009", "16306385"]}, {"Citation": "Rogers N. Cannabinoid receptor with an \u201cidentity crisis\u201d gets a second look. Nat. Med. 2015;21:966\u2013967. doi: 10.1038/nm0915-966.", "ArticleIdList": ["10.1038/nm0915-966", "26340113"]}, {"Citation": "Sun Y.-X., Xu A.-H., Yang Y., Zhang J.-X., Yu A.-W. Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells. BioMed Res. Int. 2015;2015:e874982. doi: 10.1155/2015/874982.", "ArticleIdList": ["10.1155/2015/874982", "PMC4317596", "25685815"]}, {"Citation": "Rossi F., Tortora C., Punzo F., Bellini G., Argenziano M., Di Paola A., Torella M., Perrotta S. The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma. Int. J. Mol. Sci. 2019;20:1919. doi: 10.3390/ijms20081919.", "ArticleIdList": ["10.3390/ijms20081919", "PMC6514542", "31003519"]}, {"Citation": "Camilleri M. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol. Motil. 2018;30:e13370. doi: 10.1111/nmo.13370.", "ArticleIdList": ["10.1111/nmo.13370", "PMC6150799", "29745439"]}, {"Citation": "Wright K.L., Duncan M., Sharkey K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br. J. Pharmacol. 2008;153:263. doi: 10.1038/sj.bjp.0707486.", "ArticleIdList": ["10.1038/sj.bjp.0707486", "PMC2219529", "17906675"]}, {"Citation": "McHugh D., Hu S.S., Rimmerman N., Juknat A., Vogel Z., Walker J.M., Bradshaw H.B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010;11:44. doi: 10.1186/1471-2202-11-44.", "ArticleIdList": ["10.1186/1471-2202-11-44", "PMC2865488", "20346144"]}, {"Citation": "Brown A.J. Novel cannabinoid receptors. Br. J. Pharmacol. 2007;152:567\u2013575. doi: 10.1038/sj.bjp.0707481.", "ArticleIdList": ["10.1038/sj.bjp.0707481", "PMC2190013", "17906678"]}, {"Citation": "Hua T., Vemuri K., Pu M., Qu L., Han G.W., Wu Y., Zhao S., Shui W., Li S., Korde A., et al. Crystal Structure of the Human Cannabinoid Receptor CB1. Cell. 2016;167:750\u2013762.e14. doi: 10.1016/j.cell.2016.10.004.", "ArticleIdList": ["10.1016/j.cell.2016.10.004", "PMC5322940", "27768894"]}, {"Citation": "Li X., Hua T., Vemuri K., Ho J.-H., Wu Y., Wu L., Popov P., Benchama O., Zvonok N., Locke K., et al. Crystal Structure of the Human Cannabinoid Receptor CB2. Cell. 2019;176:459\u2013467.e13. doi: 10.1016/j.cell.2018.12.011.", "ArticleIdList": ["10.1016/j.cell.2018.12.011", "PMC6713262", "30639103"]}, {"Citation": "Biringer R.G. The rise and fall of anandamide: Processes that control synthesis, degradation, and storage. Mol. Cell. Biochem. 2021;476:2753\u20132775. doi: 10.1007/s11010-021-04121-5.", "ArticleIdList": ["10.1007/s11010-021-04121-5", "33713246"]}, {"Citation": "Fezza F., Bari M., Florio R., Talamonti E., Feole M., Maccarrone M. Endocannabinoids, Related Compounds and Their Metabolic Routes. Molecules. 2014;19:17078\u201317106. doi: 10.3390/molecules191117078.", "ArticleIdList": ["10.3390/molecules191117078", "PMC6271436", "25347455"]}, {"Citation": "Maccarrone M. Tribute to Professor Raphael Mechoulam, The Founder of Cannabinoid and Endocannabinoid Research. Molecules. 2022;27:323. doi: 10.3390/molecules27010323.", "ArticleIdList": ["10.3390/molecules27010323", "PMC8746417", "35011553"]}, {"Citation": "Devane W.A., Hanu\u0161 L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science. 1992;258:1946\u20131949. doi: 10.1126/science.1470919.", "ArticleIdList": ["10.1126/science.1470919", "1470919"]}, {"Citation": "di Tomaso E., Beltramo M., Piomelli D. Brain cannabinoids in chocolate. Nature. 1996;382:677\u2013678. doi: 10.1038/382677a0.", "ArticleIdList": ["10.1038/382677a0", "8751435"]}, {"Citation": "Justinov\u00e1 Z., Yasar S., Redhi G.H., Goldberg S.R. The Endogenous Cannabinoid 2-Arachidonoylglycerol Is Intravenously Self-Administered by Squirrel Monkeys. J. Neurosci. 2011;31:7043\u20137048. doi: 10.1523/jneurosci.6058-10.2011.", "ArticleIdList": ["10.1523/jneurosci.6058-10.2011", "PMC3123903", "21562266"]}, {"Citation": "Pertwee R.G. Cannabinoids. Volume 168. Springer; Berlin/Heidelberg, Germany: 2005. Pharmacological actions of cannabinoids; pp. 1\u201351. Handbook of Experimental Pharmacology.", "ArticleIdList": ["10.1007/3-540-26573-2_1", "16596770"]}, {"Citation": "Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625\u2013E654. doi: 10.1208/aapsj070364.", "ArticleIdList": ["10.1208/aapsj070364", "PMC2751266", "16353941"]}, {"Citation": "Arif Y., Singh P., Bajguz A., Hayat S. Phytocannabinoids Biosynthesis in Angiosperms, Fungi, and Liverworts and Their Versatile Role. Plants. 2021;10:1307. doi: 10.3390/plants10071307.", "ArticleIdList": ["10.3390/plants10071307", "PMC8309193", "34203173"]}, {"Citation": "Andre C.M., Hausman J.-F., Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules. Front. Plant. Sci. 2016;7:19. doi: 10.3389/fpls.2016.00019.", "ArticleIdList": ["10.3389/fpls.2016.00019", "PMC4740396", "26870049"]}, {"Citation": "Nigro E., Formato M., Crescente G., Daniele A. Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from Cannabis sativa L. Promising Compounds? Molecules. 2021;26:2668. doi: 10.3390/molecules26092668.", "ArticleIdList": ["10.3390/molecules26092668", "PMC8124362", "34063214"]}, {"Citation": "Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes. 2006;30((Suppl. 1)):S13\u2013S18. doi: 10.1038/sj.ijo.0803272.", "ArticleIdList": ["10.1038/sj.ijo.0803272", "16570099"]}, {"Citation": "Sharma P., Murthy P., Bharath M.M.S. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran. J. Psychiatry. 2012;7:149\u2013156.", "ArticleIdList": ["PMC3570572", "23408483"]}, {"Citation": "Dhir A. Chapter 14\u2014Cannabidiol in Refractory Epilepsy. In: Atta-ur-Rahman, editor. Studies in Natural Products Chemistry. Volume 58. Elsevier; Amsterdam, The Netherlands: 2018. pp. 419\u2013438."}, {"Citation": "Laprairie R.B., Bagher A.M., Kelly M.E.M., Denovan-Wright E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 2015;172:4790\u20134805. doi: 10.1111/bph.13250.", "ArticleIdList": ["10.1111/bph.13250", "PMC4621983", "26218440"]}, {"Citation": "Perucca E., Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs. 2020;34:795\u2013800. doi: 10.1007/s40263-020-00741-5.", "ArticleIdList": ["10.1007/s40263-020-00741-5", "32504461"]}, {"Citation": "Nachnani R., Raup-Konsavage W.M., Vrana K.E. The Pharmacological Case for Cannabigerol. J. Pharmacol. Exp. Ther. 2021;376:204\u2013212. doi: 10.1124/jpet.120.000340.", "ArticleIdList": ["10.1124/jpet.120.000340", "33168643"]}, {"Citation": "Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 2008;153:199\u2013215. doi: 10.1038/sj.bjp.0707442.", "ArticleIdList": ["10.1038/sj.bjp.0707442", "PMC2219532", "17828291"]}, {"Citation": "Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009;30:515\u2013527. doi: 10.1016/j.tips.2009.07.006.", "ArticleIdList": ["10.1016/j.tips.2009.07.006", "19729208"]}, {"Citation": "Amin M.R., Ali D.W. Pharmacology of Medical Cannabis. Adv. Exp. Med. Biol. 2019;1162:151\u2013165. doi: 10.1007/978-3-030-21737-2_8.", "ArticleIdList": ["10.1007/978-3-030-21737-2_8", "31332738"]}, {"Citation": "Zagzoog A., Mohamed K.A., Kim H.J.J., Kim E.D., Frank C.S., Black T., Jadhav P.D., Holbrook L.A., Laprairie R.B. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci. Rep. 2020;10:20405. doi: 10.1038/s41598-020-77175-y.", "ArticleIdList": ["10.1038/s41598-020-77175-y", "PMC7684313", "33230154"]}, {"Citation": "Peng J., Fan M., An C., Ni F., Huang W., Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD) Basic Clin. Pharmacol. Toxicol. 2022;130:439\u2013456. doi: 10.1111/bcpt.13710.", "ArticleIdList": ["10.1111/bcpt.13710", "35083862"]}, {"Citation": "De Petrocellis L., Orlando P., Moriello A.S., Aviello G., Stott C., Izzo A.A., Di Marzo V. Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. 2012;204:255\u2013266. doi: 10.1111/j.1748-1716.2011.02338.x.", "ArticleIdList": ["10.1111/j.1748-1716.2011.02338.x", "21726418"]}, {"Citation": "De Petrocellis L., Ligresti A., Moriello A.S., Allar\u00e0 M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011;163:1479\u20131494. doi: 10.1111/j.1476-5381.2010.01166.x.", "ArticleIdList": ["10.1111/j.1476-5381.2010.01166.x", "PMC3165957", "21175579"]}, {"Citation": "Zou S., Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 2018;19:833. doi: 10.3390/ijms19030833.", "ArticleIdList": ["10.3390/ijms19030833", "PMC5877694", "29533978"]}, {"Citation": "Mang C.F., Erbelding D., Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br. J. Pharmacol. 2001;134:161\u2013167. doi: 10.1038/sj.bjp.0704220.", "ArticleIdList": ["10.1038/sj.bjp.0704220", "PMC1572920", "11522608"]}, {"Citation": "Ross G.R., Lichtman A., Dewey W.L., Akbarali H.I. Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice. Pharmacology. 2012;90:55\u201365. doi: 10.1159/000339076.", "ArticleIdList": ["10.1159/000339076", "PMC3548934", "22759743"]}, {"Citation": "Kojima S., Sugiura T., Waku K., Kamikawa Y. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur. J. Pharmacol. 2002;444:203\u2013207. doi: 10.1016/s0014-2999(02)01650-3.", "ArticleIdList": ["10.1016/s0014-2999(02)01650-3", "12063081"]}, {"Citation": "Baldassano S., Serio R., Mule\u2019 F. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. Eur. J. Pharmacol. 2008;582:132\u2013138. doi: 10.1016/j.ejphar.2007.12.016.", "ArticleIdList": ["10.1016/j.ejphar.2007.12.016", "18234188"]}, {"Citation": "Mul\u00e8 F., Amato A., Baldassano S., Serio R. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol. Res. 2007;56:132\u2013139. doi: 10.1016/j.phrs.2007.04.019.", "ArticleIdList": ["10.1016/j.phrs.2007.04.019", "17574859"]}, {"Citation": "Izzo A.A., Mascolo N., Borrelli F., Capasso F. Excitatory transmission to the circular muscle of the guinea-pig ileum: Evidence for the involvement of cannabinoid CB1 receptors. Br. J. Pharmacol. 1998;124:1363\u20131368. doi: 10.1038/sj.bjp.0701964.", "ArticleIdList": ["10.1038/sj.bjp.0701964", "PMC1565524", "9723946"]}, {"Citation": "Smid S.D., Bjorklund C.K., Svensson K.M., Heigis S., Revesz A. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur. J. Pharmacol. 2007;575:168\u2013176. doi: 10.1016/j.ejphar.2007.07.036.", "ArticleIdList": ["10.1016/j.ejphar.2007.07.036", "17706636"]}, {"Citation": "Sibaev A., Yuece B., Allescher H.D., Saur D., Storr M., Kurjak M. The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. Pharmacol. Rep. 2014;66:256\u2013263. doi: 10.1016/j.pharep.2013.09.008.", "ArticleIdList": ["10.1016/j.pharep.2013.09.008", "24911079"]}, {"Citation": "Troy-Fioramonti S., Demizieux L., Gresti J., Muller T., Verg\u00e8s B., Degrace P. Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. Diabetes. 2015;64:808\u2013818. doi: 10.2337/db14-0721.", "ArticleIdList": ["10.2337/db14-0721", "25281429"]}, {"Citation": "D\u00e9k\u00e1ny A., Benko R., Szombati V., Bartho L. The contractile effect of anandamide in the guinea-pig small intestine is mediated by prostanoids but not TRPV1 receptors or capsaicin-sensitive nerves. Basic Clin. Pharmacol. Toxicol. 2013;112:341\u2013345. doi: 10.1111/bcpt.12041.", "ArticleIdList": ["10.1111/bcpt.12041", "23216932"]}, {"Citation": "Izzo A.A., Fezza F., Capasso R., Bisogno T., Pinto L., Iuvone T., Esposito G., Mascolo N., Di Marzo V., Capasso F. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 2001;134:563\u2013570. doi: 10.1038/sj.bjp.0704293.", "ArticleIdList": ["10.1038/sj.bjp.0704293", "PMC1572987", "11588110"]}, {"Citation": "Izzo A.A., Capasso R., Aviello G., Borrelli F., Romano B., Piscitelli F., Gallo L., Capasso F., Orlando P., Di Marzo V. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br. J. Pharmacol. 2012;166:1444\u20131460. doi: 10.1111/j.1476-5381.2012.01879.x.", "ArticleIdList": ["10.1111/j.1476-5381.2012.01879.x", "PMC3417459", "22300105"]}, {"Citation": "Mascolo N., Izzo A.A., Ligresti A., Costagliola A., Pinto L., Cascio M.G., Maffia P., Cecio A., Capasso F., Di Marzo V. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J. 2002;16:1973\u20131975. doi: 10.1096/fj.02-0338fje.", "ArticleIdList": ["10.1096/fj.02-0338fje", "12397089"]}, {"Citation": "Izzo A.A., Piscitelli F., Capasso R., Aviello G., Romano B., Borrelli F., Petrosino S., Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: Relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br. J. Pharmacol. 2009;158:451\u2013461. doi: 10.1111/j.1476-5381.2009.00183.x.", "ArticleIdList": ["10.1111/j.1476-5381.2009.00183.x", "PMC2757684", "19371345"]}, {"Citation": "Begg M., Molleman A., Parsons M. Modulation of the release of endogenous gamma-aminobutyric acid by cannabinoids in the guinea pig ileum. Eur. J. Pharmacol. 2002;434:87\u201394. doi: 10.1016/s0014-2999(01)01530-8.", "ArticleIdList": ["10.1016/s0014-2999(01)01530-8", "11755170"]}, {"Citation": "Begg M., Dale N., Llaudet E., Molleman A., Parsons M.E. Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum. Br. J. Pharmacol. 2002;137:1298\u20131304. doi: 10.1038/sj.bjp.0704985.", "ArticleIdList": ["10.1038/sj.bjp.0704985", "PMC1573610", "12466239"]}, {"Citation": "Grider J.R., Mahavadi S., Li Y., Qiao L.-Y., Kuemmerle J.F., Murthy K.S., Martin B.R. Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;297:G539\u2013G549. doi: 10.1152/ajpgi.00064.2009.", "ArticleIdList": ["10.1152/ajpgi.00064.2009", "PMC2739820", "19589944"]}, {"Citation": "Capasso R., Matias I., Lutz B., Borrelli F., Capasso F., Marsicano G., Mascolo N., Petrosino S., Monory K., Valenti M., et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology. 2005;129:941\u2013951. doi: 10.1053/j.gastro.2005.06.018.", "ArticleIdList": ["10.1053/j.gastro.2005.06.018", "16143133"]}, {"Citation": "Capasso R., Izzo A.A., Fezza F., Pinto A., Capasso F., Mascolo N., Di Marzo V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol. 2001;134:945\u2013950. doi: 10.1038/sj.bjp.0704339.", "ArticleIdList": ["10.1038/sj.bjp.0704339", "PMC1573032", "11682441"]}, {"Citation": "Cluny N.L., Keenan C.M., Lutz B., Piomelli D., Sharkey K.A. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol. Motil. 2009;21:420\u2013429. doi: 10.1111/j.1365-2982.2008.01248.x.", "ArticleIdList": ["10.1111/j.1365-2982.2008.01248.x", "19140957"]}, {"Citation": "Aviello G., Matias I., Capasso R., Petrosino S., Borrelli F., Orlando P., Romano B., Capasso F., Di Marzo V., Izzo A.A. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J. Mol. Med. 2008;86:413\u2013422. doi: 10.1007/s00109-008-0305-7.", "ArticleIdList": ["10.1007/s00109-008-0305-7", "18278475"]}, {"Citation": "Stanzani A., Galiazzo G., Giancola F., Tagliavia C., De Silva M., Pietra M., Fracassi F., Chiocchetti R. Localization of cannabinoid and cannabinoid related receptors in the cat gastrointestinal tract. Histochem. Cell Biol. 2020;153:339\u2013356. doi: 10.1007/s00418-020-01854-0.", "ArticleIdList": ["10.1007/s00418-020-01854-0", "32095931"]}, {"Citation": "Anderson P.F., Jackson D.M., Chesher G.B. Interaction of delta9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J. Pharm. Pharmacol. 1974;26:136\u2013137. doi: 10.1111/j.2042-7158.1974.tb09240.x.", "ArticleIdList": ["10.1111/j.2042-7158.1974.tb09240.x", "4150831"]}, {"Citation": "Chesher G.B., Dahl C.J., Everingham M., Jackson D.M., Marchant-Williams H., Starmer G.A. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br. J. Pharmacol. 1973;49:588\u2013594. doi: 10.1111/j.1476-5381.1973.tb08534.x.", "ArticleIdList": ["10.1111/j.1476-5381.1973.tb08534.x", "PMC1776598", "4788032"]}, {"Citation": "Rosell S., Agurell S. Effects of 7-hydroxy-delta-6-tetrahydrocannabinol and some related cannabinoids on the guinea pig isolated ileum. Acta Physiol. Scand. 1975;94:142\u2013144. doi: 10.1111/j.1748-1716.1975.tb05873.x.", "ArticleIdList": ["10.1111/j.1748-1716.1975.tb05873.x", "1155164"]}, {"Citation": "Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., Corbett A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 1992;105:980\u2013984. doi: 10.1111/j.1476-5381.1992.tb09088.x.", "ArticleIdList": ["10.1111/j.1476-5381.1992.tb09088.x", "PMC1908724", "1324060"]}, {"Citation": "Pertwee R.G., Fernando S.R., Nash J.E., Coutts A.A. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 1996;118:2199\u20132205. doi: 10.1111/j.1476-5381.1996.tb15663.x.", "ArticleIdList": ["10.1111/j.1476-5381.1996.tb15663.x", "PMC1909886", "8864562"]}, {"Citation": "Jackson D.M., Malor R., Chesher G.B., Starmer G.A., Welburn P.J., Bailey R. The interaction between prostaglandin E1 and delta 9-tetrahydrocannabinol on intestinal motility and on the abdominal constriction response in the mouse. Psychopharmacologia. 1976;47:187\u2013193. doi: 10.1007/BF00735820.", "ArticleIdList": ["10.1007/BF00735820", "1273216"]}, {"Citation": "Makwana R., Molleman A., Parsons M.E. Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. Br. J. Pharmacol. 2010;159:1608\u20131622. doi: 10.1111/j.1476-5381.2009.00592.x.", "ArticleIdList": ["10.1111/j.1476-5381.2009.00592.x", "PMC2925485", "20233228"]}, {"Citation": "Capasso R., Borrelli F., Aviello G., Romano B., Scalisi C., Capasso F., Izzo A.A. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br. J. Pharmacol. 2008;154:1001\u20131008. doi: 10.1038/bjp.2008.177.", "ArticleIdList": ["10.1038/bjp.2008.177", "PMC2451037", "18469842"]}, {"Citation": "Cluny N.L., Naylor R.J., Whittle B.A., Javid F.A. The effects of cannabidiolic acid and cannabidiol on contractility of the gastrointestinal tract of Suncus murinus. Arch. Pharm. Res. 2011;34:1509\u20131517. doi: 10.1007/s12272-011-0913-6.", "ArticleIdList": ["10.1007/s12272-011-0913-6", "21975813"]}, {"Citation": "Ch\u0142opecka M., Kiraga \u0141., Crowley K., Jank M., Latek U., Mendel M., Karlik W. Diclofenac and dexamethasone modulate the effect of cannabidiol on the rat colon motility ex vivo. J. Vet. Res. 2023;67:289\u2013295. doi: 10.2478/jvetres-2023-0029.", "ArticleIdList": ["10.2478/jvetres-2023-0029", "PMC10740305", "38143819"]}, {"Citation": "Wei D., Wang H., Yang J., Dai Z., Yang R., Meng S., Li Y., Lin X. Effects of O-1602 and CBD on TNBS-induced colonic disturbances. Neurogastroenterol. Motil. 2020;32:e13756. doi: 10.1111/nmo.13756.", "ArticleIdList": ["10.1111/nmo.13756", "31802588"]}, {"Citation": "Pinto L., Izzo A.A., Cascio M.G., Bisogno T., Hospodar-Scott K., Brown D.R., Mascolo N., Di Marzo V., Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology. 2002;123:227\u2013234. doi: 10.1053/gast.2002.34242.", "ArticleIdList": ["10.1053/gast.2002.34242", "12105851"]}, {"Citation": "Okumura T., Nozu T., Ishioh M., Igarashi S., Funayama T., Kumei S., Ohhira M. Oxytocin acts centrally in the brain to improve leaky gut through the vagus nerve and a cannabinoid signaling in rats. Physiol. Behav. 2022;254:113914. doi: 10.1016/j.physbeh.2022.113914.", "ArticleIdList": ["10.1016/j.physbeh.2022.113914", "35839845"]}, {"Citation": "Lee Y., Kim Y., Park S., Heo G., Chung H.Y., Im E. Cannabinoid receptor type 1 in the aging gut regulates the mucosal permeability via miR-191-5p. Front. Endocrinol. 2023;14:1241097. doi: 10.3389/fendo.2023.1241097.", "ArticleIdList": ["10.3389/fendo.2023.1241097", "PMC10485608", "37693348"]}, {"Citation": "Alhamoruni A., Lee A.C., Wright K.L., Larvin M., O\u2019Sullivan S.E. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J. Pharmacol. Exp. Ther. 2010;335:92\u2013102. doi: 10.1124/jpet.110.168237.", "ArticleIdList": ["10.1124/jpet.110.168237", "20592049"]}, {"Citation": "Alhamoruni A., Wright K.L., Larvin M., O\u2019Sullivan S.E. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br. J. Pharmacol. 2012;165:2598\u20132610. doi: 10.1111/j.1476-5381.2011.01589.x.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01589.x", "PMC3423254", "21745190"]}, {"Citation": "Karwad M.A., Couch D.G., Theophilidou E., Sarmad S., Barrett D.A., Larvin M., Wright K.L., Lund J.N., O\u2019Sullivan S.E. The role of CB(1) in intestinal permeability and inflammation. FASEB J. 2017;31:3267\u20133277. doi: 10.1096/fj.201601346R.", "ArticleIdList": ["10.1096/fj.201601346R", "28404744"]}, {"Citation": "Wiley M.B., DiPatrizio N.V. Diet-Induced Gut Barrier Dysfunction Is Exacerbated in Mice Lacking Cannabinoid 1 Receptors in the Intestinal Epithelium. Int. J. Mol. Sci. 2022;23:10549. doi: 10.3390/ijms231810549.", "ArticleIdList": ["10.3390/ijms231810549", "PMC9504303", "36142461"]}, {"Citation": "Karwad M.A., Macpherson T., Wang B., Theophilidou E., Sarmad S., Barrett D.A., Larvin M., Wright K.L., Lund J.N., O\u2019Sullivan S.E. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPAR\u03b1. FASEB J. 2017;31:469\u2013481. doi: 10.1096/fj.201500132.", "ArticleIdList": ["10.1096/fj.201500132", "27623929"]}, {"Citation": "Karwad M.A., Couch D.G., Wright K.L., Tufarelli C., Larvin M., Lund J., O\u2019Sullivan S.E. Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPAR\u03b1. Biochem. Pharmacol. 2019;168:465\u2013472. doi: 10.1016/j.bcp.2019.07.017.", "ArticleIdList": ["10.1016/j.bcp.2019.07.017", "31325449"]}, {"Citation": "Couch D.G., Cook H., Ortori C., Barrett D., Lund J.N., O\u2019Sullivan S.E. Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial. Inflamm. Bowel Dis. 2019;25:1006\u20131018. doi: 10.1093/ibd/izz017.", "ArticleIdList": ["10.1093/ibd/izz017", "31054246"]}, {"Citation": "Maguire R.F., Wilkinson D.J., England T.J., O\u2019Sullivan S.E. The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines. Med. Cannabis Cannabinoids. 2021;4:86\u201396. doi: 10.1159/000517120.", "ArticleIdList": ["10.1159/000517120", "PMC8832208", "35224428"]}, {"Citation": "Kumar V., Mansfield J., Fan R., MacLean A., Li J., Mohan M. miR-130a and miR-212 Disrupt the Intestinal Epithelial Barrier through Modulation of PPAR\u03b3 and Occludin Expression in Chronic Simian Immunodeficiency Virus-Infected Rhesus Macaques. J. Immunol. 2018;200:2677\u20132689. doi: 10.4049/jimmunol.1701148.", "ArticleIdList": ["10.4049/jimmunol.1701148", "PMC5893401", "29514950"]}, {"Citation": "Gigli S., Seguella L., Pesce M., Bruzzese E., D\u2019Alessandro A., Cuomo R., Steardo L., Sarnelli G., Esposito G. Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells. United Eur. Gastroenterol. J. 2017;5:1108\u20131115. doi: 10.1177/2050640617698622.", "ArticleIdList": ["10.1177/2050640617698622", "PMC5721977", "29238589"]}, {"Citation": "Harvey B.S., Nicotra L.L., Vu M., Smid S.D. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine. 2013;63:209\u2013217. doi: 10.1016/j.cyto.2013.04.032.", "ArticleIdList": ["10.1016/j.cyto.2013.04.032", "23706402"]}, {"Citation": "Cocetta V., Governa P., Borgonetti V., Tinazzi M., Peron G., Catanzaro D., Berretta M., Biagi M., Manetti F., Dall\u2019Acqua S., et al. Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Front. Pharmacol. 2021;12:641210. doi: 10.3389/fphar.2021.641210.", "ArticleIdList": ["10.3389/fphar.2021.641210", "PMC8115937", "33995048"]}, {"Citation": "Silvestri C., Pagano E., Lacroix S., Venneri T., Cristiano C., Calignano A., Parisi O.A., Izzo A.A., Di Marzo V., Borrelli F. Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis. Front. Pharmacol. 2020;11:585096. doi: 10.3389/fphar.2020.585096.", "ArticleIdList": ["10.3389/fphar.2020.585096", "PMC7580385", "33162890"]}, {"Citation": "Pagano E., Iannotti F.A., Piscitelli F., Romano B., Lucariello G., Venneri T., Di Marzo V., Izzo A.A., Borrelli F. Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytother. Res. 2021;35:517\u2013529. doi: 10.1002/ptr.6831.", "ArticleIdList": ["10.1002/ptr.6831", "32996187"]}, {"Citation": "Tartakover Matalon S., Azar S., Meiri D., Hadar R., Nemirovski A., Abu Jabal N., Konikoff F.M., Drucker L., Tam J., Naftali T. Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption. Front. Endocrinol. 2021;12:685289. doi: 10.3389/fendo.2021.685289.", "ArticleIdList": ["10.3389/fendo.2021.685289", "PMC8438407", "34531823"]}, {"Citation": "Camilleri M., Carlson P., McKinzie S., Grudell A., Busciglio I., Burton D., Baxter K., Ryks M., Zinsmeister A.R. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;294:G13\u2013G19. doi: 10.1152/ajpgi.00371.2007.", "ArticleIdList": ["10.1152/ajpgi.00371.2007", "17962356"]}, {"Citation": "Fichna J., Sa\u0142aga M., Stuart J., Saur D., Sobczak M., Zatorski H., Timmermans J.-P., Bradshaw H.B., Ahn K., Storr M.A. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol. Motil. 2014;26:470\u2013481. doi: 10.1111/nmo.12272.", "ArticleIdList": ["10.1111/nmo.12272", "24460851"]}, {"Citation": "Izzo A.A., Capasso F., Costagliola A., Bisogno T., Marsicano G., Ligresti A., Matias I., Capasso R., Pinto L., Borrelli F., et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology. 2003;125:765\u2013774. doi: 10.1016/s0016-5085(03)00892-8.", "ArticleIdList": ["10.1016/s0016-5085(03)00892-8", "12949722"]}, {"Citation": "D\u2019Argenio G., Petrosino S., Gianfrani C., Valenti M., Scaglione G., Grandone I., Nigam S., Sorrentini I., Mazzarella G., Di Marzo V. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J. Mol. Med. 2007;85:523\u2013530. doi: 10.1007/s00109-007-0192-3.", "ArticleIdList": ["10.1007/s00109-007-0192-3", "17396241"]}, {"Citation": "de Filippis D., Iuvone T., d\u2019amico A., Esposito G., Steardo L., Herman A.G., Pelckmans P.A., de Winter B.Y., de Man J.G. Effect of cannabidiol on sepsis-induced motility disturbances in mice: Involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol. Motil. 2008;20:919\u2013927. doi: 10.1111/j.1365-2982.2008.01114.x.", "ArticleIdList": ["10.1111/j.1365-2982.2008.01114.x", "18373655"]}, {"Citation": "Beaumont H., Jensen J., Carlsson A., Ruth M., Lehmann A., Boeckxstaens G. Effect of \u03949-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br. J. Pharmacol. 2009;156:153\u2013162. doi: 10.1111/j.1476-5381.2008.00010.x.", "ArticleIdList": ["10.1111/j.1476-5381.2008.00010.x", "PMC2697772", "19068079"]}, {"Citation": "Zheng T., BouSaba J., Taylor A., Dilmaghani S., Busciglio I., Carlson P., Torres M., Ryks M., Burton D., Harmsen W.S., et al. A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis. Clin. Gastroenterol. Hepatol. 2023;21:3405\u20133414.e4. doi: 10.1016/j.cgh.2023.07.008.", "ArticleIdList": ["10.1016/j.cgh.2023.07.008", "PMC10800684", "37482172"]}, {"Citation": "Atieh J., Maselli D., Breen-Lyles M., Torres M., Katzka D., Ryks M., Busciglio I., Burton D., Carlson P., Harmsen W.S., et al. Cannabidiol for Functional Dyspepsia With Normal Gastric Emptying: A Randomized Controlled Trial. Am. J. Gastroenterol. 2022;117:1296\u20131304. doi: 10.14309/ajg.0000000000001805.", "ArticleIdList": ["10.14309/ajg.0000000000001805", "35537858"]}, {"Citation": "Esfandyari T., Camilleri M., Ferber I., Burton D., Baxter K., Zinsmeister A. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: A randomized, placebo-controlled study. Neurogastroenterol. Motil. 2006;18:831\u2013838. doi: 10.1111/j.1365-2982.2006.00834.x.", "ArticleIdList": ["10.1111/j.1365-2982.2006.00834.x", "16918762"]}, {"Citation": "Esfandyari T., Camilleri M., Busciglio I., Burton D., Baxter K., Zinsmeister A.R. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: A randomized, placebo-controlled study. Am. J. Physiol.-Gastrointest. Liver Physiol. 2007;293:G137\u2013G145. doi: 10.1152/ajpgi.00565.2006.", "ArticleIdList": ["10.1152/ajpgi.00565.2006", "17395895"]}, {"Citation": "Dahiya D.S., Kichloo A., Shaka H., Singh J., Edigin E., Solanki D., Eseaton P.O., Wani F. Gastroparesis with Cannabis Use: A Retrospective Study from the Nationwide Inpatient Sample. Postgrad. Med. 2021;133:791\u2013797. doi: 10.1080/00325481.2021.1940219.", "ArticleIdList": ["10.1080/00325481.2021.1940219", "34096455"]}, {"Citation": "Taylor G.H., Schwaitzberg S.D. The successful use of dronabinol for failure to thrive secondary to intestinal dysmotility. Int. J. Surg. Case Rep. 2015;11:121\u2013123. doi: 10.1016/j.ijscr.2015.04.036.", "ArticleIdList": ["10.1016/j.ijscr.2015.04.036", "PMC4446691", "25974259"]}, {"Citation": "Zemrani B., Lambe C., Goulet O. Cannabinoids Improve Gastrointestinal Symptoms in a Parenteral Nutrition-Dependent Patient With Chronic Intestinal Pseudo-Obstruction. JPEN J. Parenter. Enteral Nutr. 2021;45:427\u2013429. doi: 10.1002/jpen.1821.", "ArticleIdList": ["10.1002/jpen.1821", "32181915"]}, {"Citation": "Naftali T., Schleider L.B.-L., Dotan I., Lansky E.P., Benjaminov F.S., Konikoff F.M. Cannabis induces a clinical response in patients with Crohn\u2019s disease: A prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 2013;11:1276\u20131280.e1271. doi: 10.1016/j.cgh.2013.04.034.", "ArticleIdList": ["10.1016/j.cgh.2013.04.034", "23648372"]}, {"Citation": "van Orten-Luiten A.-C.B., de Roos N.M., Majait S., Witteman B.J.M., Witkamp R.F. Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing. Cannabis Cannabinoid Res. 2022;7:436\u2013444. doi: 10.1089/can.2020.0087.", "ArticleIdList": ["10.1089/can.2020.0087", "PMC9418368", "33998882"]}, {"Citation": "Naftali T., Mechoulam R., Gabay G., Stein A., Bronshtein M., Mari A., Konikoff F.M. 983 Cannabidiol Treatment Does Not Effect Active Crohn\u2019s Disease. Gastroenterology. 2013;5:S-180. doi: 10.1016/S0016-5085(13)60641-1.", "ArticleIdList": ["10.1016/S0016-5085(13)60641-1"]}, {"Citation": "Irving P.M., Iqbal T., Nwokolo C., Subramanian S., Bloom S.L., Prasad N., Hart A., Murray C., Lindsay J.O., Taylor A. Sa1264 A randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study to assess the symptomatic treatment of ulcerative colitis with Cannabidiol. Gastroenterology. 2015;148:S-275. doi: 10.1016/S0016-5085(15)30904-5.", "ArticleIdList": ["10.1016/S0016-5085(15)30904-5", "29538683"]}, {"Citation": "Wong B.S., Camilleri M., Busciglio I., Carlson P., Szarka L.A., Burton D., Zinsmeister A.R. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141:1638\u20131647.e1\u20137. doi: 10.1053/j.gastro.2011.07.036.", "ArticleIdList": ["10.1053/j.gastro.2011.07.036", "PMC3202649", "21803011"]}, {"Citation": "Wong B.S., Camilleri M., Eckert D., Carlson P., Ryks M., Burton D., Zinsmeister A.R. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol. Motil. 2012;24:358.e169. doi: 10.1111/j.1365-2982.2011.01874.x.", "ArticleIdList": ["10.1111/j.1365-2982.2011.01874.x", "PMC3775711", "22288893"]}, {"Citation": "Borrelli F., Fasolino I., Romano B., Capasso R., Maiello F., Coppola D., Orlando P., Battista G., Pagano E., Di Marzo V., et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013;85:1306\u20131316. doi: 10.1016/j.bcp.2013.01.017.", "ArticleIdList": ["10.1016/j.bcp.2013.01.017", "23415610"]}, {"Citation": "Pagano E., Romano B., Iannotti F.A., Parisi O.A., D\u2019Armiento M., Pignatiello S., Coretti L., Lucaf\u00f2 M., Venneri T., Stocco G., et al. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacol. Res. 2019;149:104464. doi: 10.1016/j.phrs.2019.104464.", "ArticleIdList": ["10.1016/j.phrs.2019.104464", "31553934"]}, {"Citation": "Attout H., Amichi S., Josse F., Appavoupoule V., Randriajohany A., Thirapathi Y. Cannabis Hyperemesis Syndrome: A Still Under-Recognized Syndrome. Eur. J. Case Rep. Intern. Med. 2020;7:001588. doi: 10.12890/2020_001588.", "ArticleIdList": ["10.12890/2020_001588", "PMC7213821", "32399447"]}, {"Citation": "Leu N., Routsolias J.C. Cannabinoid Hyperemesis Syndrome: A Review of the Presentation and Treatment. J. Emerg. Nurs. 2021;47:483\u2013486. doi: 10.1016/j.jen.2020.11.006.", "ArticleIdList": ["10.1016/j.jen.2020.11.006", "33712244"]}, {"Citation": "Senderovich H., Meaney C., Vashishtha S. Cannabis induced gastrointestinal tract symptoms in the adult population: A systematic review. Med. Princ Pract. 2024;33:90\u2013101. doi: 10.1159/000536161.", "ArticleIdList": ["10.1159/000536161", "PMC11096793", "38198773"]}, {"Citation": "Samuel S., Michael M., Tadros M. Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns. World J. Clin. Cases. 2023;11:4210. doi: 10.12998/wjcc.v11.i18.4210.", "ArticleIdList": ["10.12998/wjcc.v11.i18.4210", "PMC10336994", "37449231"]}, {"Citation": "Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 2003;42:327\u2013360. doi: 10.2165/00003088-200342040-00003.", "ArticleIdList": ["10.2165/00003088-200342040-00003", "12648025"]}, {"Citation": "Souza J.D.R., Pacheco J.C., Rossi G.N., de-Paulo B.O., Zuardi A.W., Guimar\u00e3es F.S., Hallak J.E., Crippa J.A., Dos Santos R.G. Adverse effects of oral cannabidiol: An updated systematic review of randomized controlled trials (2020\u20132022) Pharmaceutics. 2022;14:2598. doi: 10.3390/pharmaceutics14122598.", "ArticleIdList": ["10.3390/pharmaceutics14122598", "PMC9782576", "36559092"]}]}], "History": [{"Year": "2024", "Month": "3", "Day": "29"}, {"Year": "2024", "Month": "6", "Day": "13"}, {"Year": "2024", "Month": "6", "Day": "14"}, {"Year": "2024", "Month": "6", "Day": "27", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "6", "Day": "27", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "6", "Day": "27", "Hour": "1", "Minute": "7"}, {"Year": "2024", "Month": "6", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["38928387", "PMC11203611", "10.3390/ijms25126682", "ijms25126682"]}}]}